Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.37 |
| ▸ | KIT | P10721 | 4/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 5/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | HTR2B | P41595 | 2/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | FLT1 | P17948 | 1/20 | 0.35 |
| ▸ | FLT4 | P35916 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | TOP1 | P11387 | 2/20 | 0.33 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.33 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6101953 | 1.00 | KDR (0.37) | KDRPDGFRBKITSRCFLT3 | |
| SCHEMBL4304632 | 0.95 | PDGFRB (0.36) | KDRPDGFRBKITSRCFLT3 | |
| SCHEMBL4304634 | 0.95 | PDGFRB (0.36) | KDRPDGFRBKITSRCFLT3 | |
| SCHEMBL6103916 | 0.93 | SRC (0.38) | KDRPDGFRBKITSRCFLT3 | |
| SCHEMBL6103920 | 0.93 | SRC (0.38) | KDRPDGFRBKITSRCFLT3 | |
| SCHEMBL4304677 | 0.91 | PDGFRB (0.38) | KDRPDGFRBKITFLT3ABCB1 | |
| SCHEMBL4304673 | 0.91 | PDGFRB (0.38) | KDRPDGFRBKITFLT3ABCB1 | |
| SCHEMBL13137213 | 0.91 | MAOB (0.37) | KDRPDGFRBKITSRCMAOB | |
| SCHEMBL4305789 | 0.91 | KDR (0.39) | KDRPDGFRBKITSRCFLT3 | |
| SCHEMBL4305792 | 0.91 | KDR (0.39) | KDRPDGFRBKITSRCFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004084-A1 | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004084-A1 | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | CDK2, ERBB2, MAP3K3 | KDR 320/4885PDGFRB 502/4885KIT 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.